147 related articles for article (PubMed ID: 21843785)
1. Evaluation of (111)In labeled antibodies for SPECT imaging of mesothelin expressing tumors.
Misri R; Saatchi K; Ng SS; Kumar U; Häfeli UO
Nucl Med Biol; 2011 Aug; 38(6):885-96. PubMed ID: 21843785
[TBL] [Abstract][Full Text] [Related]
2. Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.
Lindenberg L; Thomas A; Adler S; Mena E; Kurdziel K; Maltzman J; Wallin B; Hoffman K; Pastan I; Paik CH; Choyke P; Hassan R
Oncotarget; 2015 Feb; 6(6):4496-504. PubMed ID: 25756664
[TBL] [Abstract][Full Text] [Related]
3. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
[TBL] [Abstract][Full Text] [Related]
4. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of Mesothelin-Specific Ligands for SPECT Imaging of Triple-Negative Breast Cancer.
Montemagno C; Bacot S; Ahmadi M; Kerfelec B; Baty D; Debiossat M; Soubies A; Perret P; Riou L; Fagret D; Broisat A; Ghezzi C
J Nucl Med; 2018 Jul; 59(7):1056-1062. PubMed ID: 29572256
[TBL] [Abstract][Full Text] [Related]
6. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.
Prantner AM; Yin C; Kamat K; Sharma K; Lowenthal AC; Madrid PB; Scholler N
Mol Pharm; 2018 Apr; 15(4):1403-1411. PubMed ID: 29462558
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe.
Misri R; Meier D; Yung AC; Kozlowski P; Häfeli UO
Nanomedicine; 2012 Aug; 8(6):1007-16. PubMed ID: 22100757
[TBL] [Abstract][Full Text] [Related]
9. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
Sato N; Hassan R; Axworthy DB; Wong KJ; Yu S; Theodore LJ; Lin Y; Park L; Brechbiel MW; Pastan I; Paik CH; Carrasquillo JA
J Nucl Med; 2005 Jul; 46(7):1201-9. PubMed ID: 16000290
[TBL] [Abstract][Full Text] [Related]
11. C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model.
Sogawa C; Tsuji AB; Sudo H; Sugyo A; Yoshida C; Odaka K; Uehara T; Arano Y; Koizumi M; Saga T
Nucl Med Biol; 2010 Feb; 37(2):179-87. PubMed ID: 20152717
[TBL] [Abstract][Full Text] [Related]
12. Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model.
Yoshida C; Sogawa C; Tsuji AB; Sudo H; Sugyo A; Uehara T; Hino O; Yoshii Y; Fujibayashi Y; Fukumura T; Koizumi M; Arano Y; Saga T
Nucl Med Commun; 2010 May; 31(5):380-8. PubMed ID: 20072072
[TBL] [Abstract][Full Text] [Related]
13. In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
Huhtala T; Laakkonen P; Sallinen H; Ylä-Herttuala S; Närvänen A
Nucl Med Biol; 2010 Nov; 37(8):957-64. PubMed ID: 21055627
[TBL] [Abstract][Full Text] [Related]
14. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.
Hassan R; Wu C; Brechbiel MW; Margulies I; Kreitman RJ; Pastan I
Int J Cancer; 1999 Feb; 80(4):559-63. PubMed ID: 9935157
[TBL] [Abstract][Full Text] [Related]
15. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
16. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
17. ¹¹¹In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages.
Terry SY; Boerman OC; Gerrits D; Franssen GM; Metselaar JM; Lehmann S; Oyen WJ; Gerdes CA; Abiraj K
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1430-8. PubMed ID: 26012900
[TBL] [Abstract][Full Text] [Related]
18. 131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging.
Chen L; Wang L; Yan J; Ma C; Lu J; Chen G; Chen S; Su F; Wang W; Su X
Int J Oncol; 2017 Feb; 50(2):649-659. PubMed ID: 28000859
[TBL] [Abstract][Full Text] [Related]
19. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
20. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
